- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00802191
WiiMote Game Controller as a Device to Study Movement Disorders
Purpose of the study:
The purpose of this study is to investigate the Wii remote game control device for use in the study of Movement Disorders. The term "Movement Disorders" refers to a group of abnormal medical conditions characterized by involuntary body movements. Current treatment of these disorders is primarily geared to improve symptoms. Rating scales are usually used to grade response to treatment. These rating scales require special training, take a lot of time, and often present with great variability. Thus, the development of a simple device to perform efficacy measurements offers a great advantage over current methods and is less costly.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
The expected length of taking part in this study will depend on whether or not subjects are chosen for a group to look at the reproducibility of the data collected from the Wii remote. If subjects agree to take part in the study, basic data including age, gender, ethnicity, and medications will be collected. If subjects have been diagnosed with a movement disorder, that diagnosis will also be recorded. This data will be secured in a HIPAA compliant computer system and recorded data will be given a unique random code. During the Wii remote portion of the study, subjects will be asked to hold the Wii remote controller in several different positions and perform various movements with the controller.
These include:
- Holding the controller still with the elbow straight and then the elbow bent.
- Tapping the control button as fast as you can.
- Rotation of your wrist as fast as you can.
- Bending at the wrist and at the elbow as fast as you can.
- Walking 30 feet.
- Attaching the controller to your arm with a Velcro strap and repeating the motions performed while holding the controller.
These maneuvers will be done first with the right and then the left hand. We expect that this series will take about 5 minutes.
If subjects have Parkinson's disease they will also be asked to undergo Part III (Motor Sub-Scale) of the Unified Parkinson's Disease Rating Scale. This scale measures various aspects such as finger tapping, hand opening and closing and walking on a scale of 0 - 4. We expect that this portion of the examination will take about 5 minutes.
If subjects carry the diagnosis of Essential Tremor, they will be asked to undergo Standard Measure of EssentialTremor that includes drawing of spirals and pouring of water from one glass to another. Again, we estimate that this scale will take about 5 minutes.
If subjects carry the diagnosis of Parkinson's disease or Essential Tremor and have deep brain stimulation surgery, results of using the Wii™ Remote game controller (handheld or attached using a Velcro strap) will be done during a clinical programming appointment. The information obtained will not be used for any clinical use and will not interfere with the normal standard of care.
A sub-set of patients will be asked to repeat these measures at various times to see if there is either a learning curve, or if the measures are repeatable over time. Subjects may decline this at any point in time.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232-2551
- Vanderbilt University Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Men and women, aged 18 or older, with abnormal movements (including tremor, chorea, dystonia, myoclonus, and tic) and normal controls (subjects without abnormal movements).
- Subjects must be willing and able to comply with study procedures.
- Patients must be willing and able to give meaningful, written informed consent.
Exclusion Criteria:
1. Significant cognitive impairment which, in the opinion of the Investigator, would interfere with the ability to complete all the tests required in the protocol.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Control de caso
- Perspectivas temporales: Transversal
Cohortes e Intervenciones
Grupo / Cohorte |
---|
Control Group
Participants with no movement disorders.
|
Movement Disorders Participants
Participants have a movement disorder
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Thomas L Davis, MD, Department of Neurology/Movement Disorders
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TDavis Wii
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Enfermedad de Parkinson
-
ProgenaBiomeReclutamientoEnfermedad de Parkinson | Enfermedad de Parkinson con demencia | Síndrome de Parkinson-Demencia | Enfermedad de Parkinson 2 | Enfermedad de Parkinson 3 | Enfermedad de Parkinson 4Estados Unidos
-
National Heart, Lung, and Blood Institute (NHLBI)TerminadoEnfermedad de Parkinson 6, inicio temprano | Enfermedad de Parkinson (autosómica recesiva, aparición temprana) 7, humana | Enfermedad de Parkinson Autosómica Recesiva, Inicio Temprano | Enfermedad de Parkinson, autosómica recesiva de aparición temprana, digénica, Pink1/Dj1Estados Unidos
-
Assiut UniversityAún no reclutandoMri en Parkinson
-
Medical College of WisconsinRetirado
-
Hacettepe UniversityTerminadoEnfermedad de Parkinson idiopáticaPavo
-
Pôle Saint HélierRennes University Hospital; Réseau Parkinson BretagneTerminadoEnfermedad de Parkinson | Síndrome de ParkinsonFrancia
-
UCB PharmaTerminadoEnfermedad de Parkinson idiopáticaAlemania
-
Samuel Vilchez, PhDNational Autonomous University of Nicaragua; Wake Forest University; GID BIO, Inc. y otros colaboradoresTerminadoEnfermedad de Parkinson y parkinsonismo | Enfermedad de Parkinson idiopáticaNicaragua
-
AbbVie (prior sponsor, Abbott)Quintiles, Inc.TerminadoEnfermedad de Parkinson avanzadaEstados Unidos, Nueva Zelanda
-
UCB BIOSCIENCES GmbHOtsuka Pharmaceutical Co., Ltd.TerminadoEnfermedad de Parkinson Idiopática AvanzadaCorea, república de, Estados Unidos, Malasia, Singapur, Taiwán